Admedus : Director Appointment/Resignation

Admedus Ltd

ABN 35 088 221 078

REGISTERED OFFICE:

26 Harris Road Malaga Western Australia 6090

ASX ANNOUNCEMENT

• Mr. Michael Bennett resigns as Executive Director

• Mr. Simon Buckingham appointed as Non-Executive Director

Brisbane, Australia, 17 February 2017

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info.au@admedus.com

www.admedus.com

Admedus Limited (ASX: AHZ) today announced that Mr. Michael Bennett has resigned as Executive Director of the Company, effective 17 February 2017.

Mr. Wayne Paterson, Chairman and Interim CEO said: "The Board of Admedus would like to express its gratitude to Mr. Bennett for the contributions he has made to the Company over the past 12 years. We wish him all the best for the future."

The Company further announced the appointment of Mr. Simon Buckingham to its Board of Directors as a Non-Executive Director.

Mr. Buckingham has more than 25 years' experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Now based in Sydney, Mr. Buckingham is currently a senior global advisor to Actelion, one of the world's leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Mr. Buckingham served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US. From 1998-2000 he worked in sales and marketing for Parke-Davis (now part of Pfizer) in the US and prior to that served at Roche, both in Switzerland and Australia.

Mr. Buckingham is currently a non-executive director of: Pharmaxis Ltd (ASX), an Australian pharmaceutical research company with a portfolio including two respiratory products approved in various world markets and a research pipeline focused on areas of high unmet clinical need in inflammatory and fibrotic diseases; Creso Pharma Ltd (ASX), specialising in cannabis derived pharmaceutical-grade nutriceutical products for human and animal health; Vaxxilon AG, a European based start-up, founded by the Max Planck Society and Actelion, dedicated to the discovery, development and commercialisation of innovative synthetic carbohydrate vaccines; and the Can Too Foundation, a non- profit organisation promoting health and wellbeing while raising funds for cancer research.

Mr. Buckingham holds a Bachelor of Veterinary Science degree from the University of Sydney, a PhD from the University of Melbourne, a Graduate Management Qualification from the AGSM, University of NSW and is a Graduate of the Australian Institute of Company Directors.

"Simon Buckingham brings to Admedus an extremely impressive depth of experience and a full spectrum of the most relevant qualifications. The Board welcomes him to Admedus and looks forward to his insight and contribution as we continue the Company's progress with growth and expansion", said Mr. Paterson.

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

Signal Leadership Communication Inc. Mr Bob Pickard

Tel: +1 (647) 822 1000

bob.pickard@signaleadership.com

FTI Consulting

Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

Rx Communications Group, LLC Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com